SCHEMBL12496095

SCHEMBL12496095

COc1ccc(C2CC(c3cccc(OC)c3)=NN2c2ccc(C(=O)O)cc2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ PDE5A O76074 12/20 1.00
▸ NR3C2 P08235 2/20 0.73
▸ L3MBTL1 Q9Y468 3/20 0.71
▸ GLA P06280 2/20 0.71
▸ POLB P06746 1/20 0.71
▸ ATM Q13315 1/20 0.70
▸ RXFP1 Q9HBX9 1/20 0.70
▸ PTGS2 P35354 2/20 0.69
▸ MEN1 O00255 2/20 0.65
▸ KMT2A Q03164 2/20 0.65
▸ KDM4E B2RXH2 1/20 0.63
▸ ALDH1A1 P00352 1/20 0.63
▸ GAA P10253 1/20 0.63
▸ MAPT P10636 1/20 0.63
▸ NPSR1 Q6W5P4 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12493661 0.91 PDE5A (1.00) PDE5ANR3C2L3MBTL1GLAPOLB
SCHEMBL11121023 0.89 PDE5A (0.91) PDE5ANR3C2L3MBTL1GLAPOLB
SCHEMBL11121205 0.89 PDE5A (0.91) PDE5ANR3C2L3MBTL1GLAPOLB
SCHEMBL11119541 0.89 PDE5A (0.91) PDE5ANR3C2L3MBTL1GLAPOLB
SCHEMBL12494300 0.87 PDE5A (1.00) PDE5ANR3C2L3MBTL1GLAPOLB
SCHEMBL12492697 0.84 PDE5A (1.00) PDE5ANR3C2L3MBTL1GLAPOLB
SCHEMBL9626269 0.83 PDE5A (0.71) PDE5AL3MBTL1GLAPOLBATM
SCHEMBL18826382 0.82 L3MBTL1 (0.84) PDE5AL3MBTL1GLAATMPTGS2
SCHEMBL15301136 0.82 KDM4E (0.88) PDE5ANR3C2L3MBTL1GLAPOLB
SCHEMBL12495092 0.81 PDE5A (1.00) PDE5ANR3C2L3MBTL1GLAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9388139-B2 Derivatives of celeboxib, use thereof and preparation thereof GERMAN UNIVERSITY (EG) 2016-07-12 — — US disclosed
US-9388139-B2 Derivatives of celeboxib, use thereof and preparation thereof GERMAN UNIVERSITY (EG) 2016-07-12 — — US disclosed
US-20140171477-A1 DERIVATIVES OF CELEBOXIB, USE THEREOF AND PREPARATION THEREOF SOUTHERN RESEARCH INSTITUTE 2014-06-19 — — US disclosed
US-20140171477-A1 DERIVATIVES OF CELEBOXIB, USE THEREOF AND PREPARATION THEREOF SOUTHERN RESEARCH INSTITUTE 2014-06-19 — — US disclosed
WO-2012125884-A1 DERIVATIVES OF CELECOXIB, USE THEREOF AND PREPARATION THEREOF SOUTHERN RESEARCH INSTITUTE (US) 2012-09-20 — — WO disclosed
WO-2012125884-A1 DERIVATIVES OF CELECOXIB, USE THEREOF AND PREPARATION THEREOF SOUTHERN RESEARCH INSTITUTE (US) 2012-09-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140171477-A1 DERIVATIVES OF CELEBOXIB, USE THEREOF AND PREPARATION THEREOF PDE5A, PDE3A, PDE3B PDE5A 1/4885NR3C2 373/4885L3MBTL1 2528/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback